Holen Sie sich die Stockscreener-App
4.32
9.09%
0.36
Handel nachbörslich:
4.28
-0.04
-0.93%
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics enters into exclusive license agreement for two drugs - Pennsylvania Business Report
Equities Analysts Offer Predictions for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Leerink Partners - Defense World
Aclaris Therapeutics director acquires $1.5 million in stock By Investing.com - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Leerink Partnrs to Strong-Buy Rating - MarketBeat
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies - MSN
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - MSN
S&P 500 Value (IVX) QuotePress Release - The Globe and Mail
Aclaris signs license deal for biologics assets - MSN
Aclaris stock soars for second day on licensing deal, analyst upgrades - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at BTIG Research - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Jefferies Financial Group to “Buy” Rating - Defense World
Aclaris stock sees over 120% upside potential with bolstered immunology assets - Investing.com India
Aclaris Therapeutics Enters Exclusive Agreements and Announces Private PlacementWAYNE, Pa., Nov. 16, 2024 /PRNewswire/ — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has recently entered into significant agreements and a private placement. On Nov - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Raised to “Overweight” at Piper Sandler - Defense World
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG - Yahoo Finance
S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News - MarketWatch
Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha
Aclaris gains global rights to Biosion's inflammatory treatment candidates By Investing.com - Investing.com UK
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps - MSN
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Aclaris back on track with new money and promising deal - The Pharma Letter
Aclaris Therapeutics secures global rights to Biosion’s antibodies - Yahoo Finance
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink Partners - MarketBeat
Leerink Partners Upgrades Aclaris Therapeutics (ACRS) - MSN
Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink - TipRanks
Aclaris Therapeutics (NASDAQ:ACRS) Raised to Buy at Jefferies Financial Group - MarketBeat
Jefferies says buy this pharmaceutical play, sees more than 100% upside from here - Head Topics
Aclaris to license Biosion’s two biologics assets for up to $940m - World Pharmaceutical Frontiers
Aclaris stock boosted by BTIG on transformative AD drug acquisition and outlook - Investing.com
Aclaris shares retain Hold rating at Stifel, price target reaffirmed - Investing.com
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo - BioCentury
Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors - Marketscreener.com
Aclaris Therapeutics (ACRS): Strategic Alliance with Biosion Ignites 53% Stock Surge - BP Journal
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
Aclaris stock rallies 53% amid licensing deal, Piper upgrade (NASDAQ:ACRS) - Seeking Alpha
Aclaris secures $80 million in private stock sale By Investing.com - Investing.com South Africa
Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler - TipRanks
Aclaris shares surge on licensing deal valued at up to nearly $1 billion - The Business Journals
Aclaris (ACRS) Gains Momentum With Strategic Business Expansion - Stocks Telegraph
Biosion sells antibody rights to Aclaris in $940M deal - BioWorld Online
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More
Aclaris secures $80 million in private stock sale - Investing.com
Aclaris secures rights to novel immunology biologics - Investing.com
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - The Manila Times
Aclaris Therapeutics Expands Pipeline and Strengthens Leadership - TipRanks
Aclaris Therapeutics enters global license agreement with Biosion - TipRanks
Aclaris Therapeutics Announces Exclusive, Global License - GlobeNewswire
Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewswire
Aclaris Therapeutics, Inc. Announces Executive Appointments - Marketscreener.com
Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc - GuruFocus.com
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Position Boosted by BML Capital Management LLC - MarketBeat
0.98%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):